Extended Data Fig. 7: Glycolytic metabolism enhances cell survival and cell proliferation.
From: A unique subset of glycolytic tumour-propagating cells drives squamous cell carcinoma
Extended Data Fig. 7 (related to Fig. 3). a, Apoptosis assay in HSC2 cells pretreated with doxycycline for at least 4 days. Propidium iodide (PI) and annexin V double positive cells were considered as dead cells. Data indicate mean ± S.D. Data are from three independent experiments (n = 10 each sample). Student’s t-tests were performed (two-sided). b, Cell proliferation assay in SCC13 cells pretreated with doxycycline for at least 3 days with or without DCA over time. Data indicate mean ± S.E.M. (left). Western blot analysis of whole cell lysates was performed at day 5 in the cell proliferation assay (right). Data are from three independent experiments. Two-way ANOVA test was performed. c, Schematic presentation of skin xenotransplantation assay in severely immunocompromised NSG (NOD/SCID/Il2rg-/-) mice. Doxycycline was administered in drinking water. HPKs; human primary keratinocytes, TAFs; tumour-associated fibroblasts d, In vivo growth of SCC13 cells was monitored by bioluminescence imaging over time. Normalized total flux ratio of each mouse was used to track in vivo tumor growth (left). Representative bioluminescence images of tumours with control or SIRT6-deficient SCC13 cells at day 61 (right). Two-way ANOVA test was performed. e, Knockdown of SIRT6 by in vivo doxycycline administration in tumours was confirmed by immunohistochemistry. Scale bars indicate 100µm. Immunostaining was performed two times with similar results. * p<0.05, *** p<0.001.
